6-K 1 telix-6kforq22026tradingup.htm 6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of July, 2026
Commission File Number: 001-42128
Telix Pharmaceuticals Limited
(Translation of registrant’s name into English)
55 Flemington Road
North Melbourne, Victoria 3051, Australia
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-
F.
Form 20-F ☒ Form 40-F ☐
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
On July 21, 2026 (Melbourne, Australia), Telix Pharmaceuticals Limited filed an announcement with the Australian
Securities Exchange titled “Q2 2026 Revenue US$247M Strong Momentum Pipeline Progress” a copy of which is
attached to this Form 6-K as Exhibit 99.1.

99.1 | Press release – July 21, 2026

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.

|  | Telix Pharmaceuticals Limited
Date: | July 21, 2026 | By: | /s/ Christian Krautkramer
|  |  | Name: Christian Krautkramer
|  |  | Title: Group General Counsel